BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company. The non-exclusive license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms and broad rights to use the Alloy platforms for antibody drug discovery and development under this multi-year collaboration..

波士顿--（商业新闻短讯）--Alloy Therapeutics是一家致力于实现生物制剂药物发现平台和服务民主化的生物技术生态系统公司，今天宣布与礼来公司（Eli Lilly and company）就其鼠类平台的全人抗体发现达成许可协议。该非排他性许可证为礼来提供了ATX Gx™和ATX-CLC™鼠标平台的访问权限，以及在这项多年合作下使用合金平台进行抗体药物发现和开发的广泛权利。。

Launched in 2019, the Alloy ATX-Gx platform has rapidly become the industry standard fully human transgenic mouse platform to enable therapeutic discovery programs utilized by over 170 partners. Alloy is dedicated to reinvesting its revenue into innovation and has continuously expanded its murine platforms, adding new strains such as ATX-GL™ with the full human lambda repertoire as well as ATX-GKH™ hyperimmune strain for increased generation of antigen-specific B-cells and enhanced IgG class switching.

合金ATX Gx平台于2019年推出，已迅速成为行业标准的全人类转基因小鼠平台，可实现170多个合作伙伴使用的治疗发现计划。Alloy致力于将其收入重新投资于创新，并不断扩大其鼠类平台，添加了新菌株，例如具有完整人类λ库的ATX-GL™以及ATX-GKH™超免疫菌株，以增加抗原特异性B细胞的产生并增强IgG类别转换。

In 2023 Alloy launched the ATX-CLC platform expressing common light chain antibodies with full heavy chain diversity to enable efficient, modular bispecific discovery..

2023年，Alloy推出了ATX-CLC平台，该平台表达具有全重链多样性的常见轻链抗体，以实现高效，模块化的双特异性发现。。

Access to Alloy’s platforms extends to Lilly’s Catalyze360™ program, a comprehensive platform designed to enable drug discovery and development for biotech partners, including opportunities for capital investment, world-class lab space, and exceptional R&D capabilities and expertise. Under the arrangement, biotech companies that work with Lilly Catalyze360 will have the opportunity for Alloy antibody discovery platforms to be deployed to rapidly progress partnered discovery campaigns and accelerate medicines to the clinic for patients..

获得Alloy平台的机会延伸到礼来的Catalyste360™计划，该计划是一个综合平台，旨在为生物技术合作伙伴提供药物发现和开发，包括资本投资机会、世界一流的实验室空间以及卓越的研发能力和专业知识。根据该安排，与礼来Catalyste360合作的生物技术公司将有机会部署合金抗体发现平台，以快速推进合作发现活动，并加速患者的药物进入诊所。。

“Lilly is a great collaboration partner, and we are excited to further enable the company’s broader R&D ecosystem with access to Alloy’s best-in-class technologies for discovering superior fully human antibodies and bispecifics against even the most challenging targets,” said Heather Schwoebel, CBO of Antibodies and Strategic Collaborations at Alloy.

Alloy抗体与战略合作CBO Heather Schwoebel表示：“礼来是一个很好的合作伙伴，我们很高兴能够进一步使公司更广泛的研发生态系统能够获得Alloy一流的技术，以发现针对最具挑战性目标的优质全人抗体和双特异性抗体。”。

“This collaboration represents just one example of the many ways Alloy is flexible in enabling our partners with a breadth of discovery solutions to support their objectives and improve patient lives.”.

“这项合作只是Alloy灵活运用多种方法的一个例子，Alloy能够为我们的合作伙伴提供广泛的发现解决方案，以支持他们的目标并改善患者的生活。”。

About Alloy Therapeutics

关于合金疗法

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery.

Alloy Therapeutics是一家生物技术生态系统公司，授权全球科学界共同生产更好的药物。通过学术界、生物技术界和最大的生物制药界的合作伙伴社区，Alloy将竞争前工具、技术、服务和公司创建能力的获取民主化，这些能力是发现和开发六种治疗性生物制剂的基础：抗体、TCR、基因药物、肽、细胞疗法和药物输送。

Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation..

合作伙伴可以通过发现服务关系或通过Alloy的创新订阅服务获得所有当前和未来的技术。Alloy将其收入的100%用于创新和获取创新，这反映了Alloy对科学界的不懈承诺。。